Tip of the Month
Publishing date: December 2011
Tip Editors: Ann Hoste, John Salmon and John Thygesen
Tip reviewer: Roger Hitchings
The Science behind the Tip
Neovascular glaucoma is a devastating consequence of diseases like proliferative diabetic retinopathy and ischaemic central retinal vein occlusion. New vessel formation on the iris results from the release of vascular endothelial growth factor (VEGF) by ischaemic retina (1).
In patients who present with neovascular glaucoma, the immediate injection of 1.25 mg of bevacizumab into the vitreous before pan-retinal photocoagulation (PRP), results in a significant regression of iris new vessels within two days (2). In the early stages of the disease, many patients have concomitant decrease in intraocular pressure (IOP) lasting several months (3). In patients with refractory neovascular glaucoma who are unsuitable for PRP, pain is reduced within one week of the injection, but there is no effect on IOP (4).
Contributor: John Salmon, Oxford
1. Ichhpujini P, Ramasubramanian A, Kaushik S, et al. Bevacizumab in glaucoma: a review. Can J Ophthalmol. 2007;42:812-15.
2. Moraczewski AL, Lee RK, Palmberg PF, et al. Outcomes of treatment of neovascular glaucoma with intravitreal bevacizumab. Br J Ophthalmol. 2009;93:589-93.
3. Wakabayashi T, Oshimia Y, Sakaguchi H, et al. Intraocular bevacizumab to treat iris neovascularisation and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmol. 2008; 115:1571-80.
4. Kotecha A, Spratt A, Ogunbowale L, et al. Intravitreal bevacizumab in refractory neovascular glaucoma: a prospective observational case series. Arch Ophthalmol. 2011;129:145-50.